A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung

Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR is a cAMP-regulated ion channel used for the transport of anions across epithelial cells [1]. Mutations in this gene result in a thickening of mucosal secretions, primarily in the respiratory and gastrointestinal systems [1]. Common clinical manifestations of this disease include, but are not limited to, chronic polymicrobial sino-pulmonary infections, male infertility, decreased lung function, and pancreatic insufficiency [1].

Source: Journal of Cystic Fibrosis - November 22, 2021 Category: Respiratory Medicine Authors: Lo M. Sosinski, Christian Martin H, Kerri A. Neugebauer, Lydia-Ann J. Ghuneim, Douglas V. Guzior, Alicia Castillo-Bahena, Jenna Mielke, Ryan Thomas, Marc McClelland, Doug Conrad, Robert A. Quinn Source Type: research